Jeff Yass’s PharmaCyte Biotech PMCB Stock Holding History

Jeff Yass’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,700	Closed	-$34K	–	12888
2023 Q1	$34K	Sell	11,700 -24,400	-68%	-$71.7K	﹤0.01%	11861
2022 Q4	$105K	Buy	36,100 +1,400	+4%	+$4.01K	﹤0.01%	10920
2022 Q3	$83K	Buy	+34,700	New	+$87.8K	﹤0.01%	11853
2022 Q2	–	Sell	-43,000	Closed	-$99K	–	13700
2022 Q1	$99K	Buy	+43,000	New	+$95.5K	﹤0.01%	11924
2021 Q4	–	Sell	-30,100	Closed	-$95K	–	13727
2021 Q3	$95K	Buy	+30,100	New	+$106K	﹤0.01%	12100

Other funds holding PMCB

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Jeff Yass's PMCB Position: Q2 2026 in Review

Jeff Yass opened a new position in PharmaCyte Biotech (PMCB) in Q2 2026: 44,853 shares worth $34.5K. The stake represents ﹤0.01% of the portfolio and ranks #12930 among its holdings. This is a return to the name: Jeff Yass previously reported a position in PMCB as recently as Q2 2025.

Jeff Yass first reported a position in PMCB in Q1 2022 and has held it in 12 quarters since. The position peaked at $311K in Q1 2023. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

Jeff Yass held 44,853 shares of PharmaCyte Biotech worth $34.5K as of Q2 2026.
PharmaCyte Biotech was a new Jeff Yass position in Q2 2026.
PharmaCyte Biotech made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12930 holding.
Jeff Yass first reported a position in PharmaCyte Biotech in Q1 2022 and has held it in 12 quarters since.
Jeff Yass's PharmaCyte Biotech position peaked at $311K in Q1 2023.
28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.